Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Patient with type 2 diabetes mellitus (T2DM) diagnosed for at least 1 year before the screening visit (V1).~* Patient treated with a stable, once a day basal insulin regimen (ie, type of insulin and time/frequency of the injection), for at least 3 months before the screening visit.~* The total daily basal insulin dose should be stable (± 20%) and \<15 U/day for at least 1 month before the screening visit.~* Patient receiving 1 or 2 oral anti-diabetic drugs (OADs): the OAD dose(s) must be stable during the 3 months before the screening visit. The OADs can be 1 to 2 out of:~* Metformin;~* Sulfonylurea (SU);~* Glinide;~* Dipeptidyl-peptidase-4 (DPP-4) inhibitor;~* Sodium glucose co-transporter 2 (SGLT2) inhibitor;~* Alpha glucosidase inhibitor (alpha-GI).~* Signed written informed consent.~Exclusion criteria:~* Age \<20 years at screening visit.~* HbA1c at screening visit \<7.5% or \>9.5%.~* Fasting plasma glucose (FPG) \>180 mg/dL (10.0 mmol/L) at screening visit.~* Pregnancy or lactation, women of childbearing potential with no effective contraceptive method.~* Use of oral or injectable glucose-lowering agents other than those stated in the inclusion criteria in the 3 months before screening visit.~* Previous use of insulin regimen other than basal insulin, eg, prandial or pre-mixed insulin.~Note: Short-term treatment (≤10 days) due to intercurrent illness including gestational diabetes is allowed at the discretion of the Investigator.~* Use of thiazolidinedione (TZD) within 6 months prior to screening visit.~* History of discontinuation of a previous treatment with a glucagon-like peptide-1(GLP-1) receptor agonist due to safety/ tolerability issues or lack of efficacy.~* Laboratory findings at the screening visit; including:~* Amylase and/or lipase \>3 times the upper limit of the normal (ULN) laboratory range;~* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3 ULN;~* Calcitonin ≥20 pg/mL (5.9 pmol/L);~* Positive serum pregnancy test.~* Any contraindication to metformin use according to local labeling.~* History of hypersensitivity to any GLP-1 receptor agonist or to metacresol.~* Contraindication to use of insulin glargine or lixisenatide according to local labeling. History of hypersensitivity to insulin glargine or to any of the excipients.~* Personal or immediate family history of medullary thyroid cancer (MTC) or genetic condition that predisposes to MTC (eg, multiple endocrine neoplasia syndromes).~* History of pancreatitis (unless pancreatitis was related to gallstones and cholecystectomy has now been performed), pancreatitis during previous treatment with incretin therapies, chronic pancreatitis, pancreatectomy, stomach/gastric surgery.~* Exclusion criteria for randomization at the end of the run-in phase:~* HbA1c \<7.5% or \>9.5% at visit 6 (Week -1).~* Mean fasting self monitored plasma glucose (SMPG) \>160 mg/dL (8.9 mmol/L), calculated from all available (minimum of 4 self-measurements) values during the 7 days prior to randomization.~Note:fasting SMPG on the day of randomization can be included if assessed before randomization.~* Average insulin glargine daily dose ≥15 U/day or \<5U/day calculated for the last 3 days before Visit 7.~* Metformin total daily dose \<750 mg/day.~* Amylase and/or lipase \>3 ULN at Visit 6 (Week -1).~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LixiLan (Type: EXPERIMENTAL): LixiLan (insulin glargine/lixisenatide fixed ratio combination) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.~Metformin will be continued.
- insulin glargine (Type: ACTIVE_COMPARATOR): Insulin glargine U100 (Lantus) will be injected subcutaneously (under skin) once daily. Dose will be individually adjusted.~Metformin will be continued.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete